FDA advisors back brodalumab with suicide risk plan
Valeant’s skin jab brodalumab has taken a big step towards US approval after regulatory advisors backed the drug for adult patients with moderate-to-severe plaque psoriasis.
Read More
Tag: Relistor
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
